AstraZeneca and Schering Announce Collaboration and Licensing Agreement

AstraZeneca and Schering AG, Germany, have entered into a research collaboration and licensing agreement in the area of Selective Glucocorticoid Receptor Agonists, SEGRAs, which represent a new class of anti-inflammatory agents.

Under the terms of the three-year agreement, AstraZeneca will have an exclusive worldwide license to develop and market compounds for rheumatoid and respiratory diseases, while Schering will have an exclusive worldwide license for all other indications. Schering will receive upfront fees, with both parties having the potential to benefit from downstream milestone payments and royalties.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies, with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products.

For further information please contact:

Staffan Ternby,

Information Director

Tel: +46 0 70 557 4300

Email: staffan.ternby@astrazeneca.com

Or visit: http://www.astrazeneca.com